度普利尤单抗给药方案对持续性病情得到控制的特应性皮炎患者的疗效评估。 - Suppr

Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.

作者信息

Sánchez-García V, Navarro-Triviño F J, Silvestre J F

机构信息

Dermatology Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Dermatology Department, San Cecilio University Hospital, Granada, Spain.

出版信息

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1426-e1429. doi: 10.1111/jdv.19348. Epub 2023 Jul 21.

DOI:10.1111/jdv.19348

PMID:37458506

Abstract

摘要

相似文献

Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1426-e1429. doi: 10.1111/jdv.19348. Epub 2023 Jul 21.

Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?

J Eur Acad Dermatol Venereol. 2023 May;37(5):e691-e692. doi: 10.1111/jdv.18908. Epub 2023 Feb 6.

Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study.

Int J Dermatol. 2024 Mar;63(3):402-404. doi: 10.1111/ijd.17030. Epub 2024 Jan 16.

Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.

Dermatitis. 2024 Jan-Feb;35(S1):S107-S108. doi: 10.1089/derm.2023.0052. Epub 2023 Aug 18.

Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.

Br J Dermatol. 2023 Jul 17;189(2):e39. doi: 10.1093/bjd/ljad201.

Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.

JAMA Dermatol. 2024 Mar 1;160(3):370. doi: 10.1001/jamadermatol.2023.6198.

A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.

J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18.

Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e35-e38. doi: 10.1111/jdv.19409. Epub 2023 Aug 24.

Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.

J Dermatol. 2024 Mar;51(3):e63-e65. doi: 10.1111/1346-8138.17017. Epub 2023 Nov 10.

Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab.

J Invest Dermatol. 2023 Sep;143(9):1822-1825.e3. doi: 10.1016/j.jid.2023.03.1659. Epub 2023 Mar 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.

作者信息

Sánchez-García V, Navarro-Triviño F J, Silvestre J F

机构信息

Dermatology Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Dermatology Department, San Cecilio University Hospital, Granada, Spain.

出版信息

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1426-e1429. doi: 10.1111/jdv.19348. Epub 2023 Jul 21.

DOI:10.1111/jdv.19348

PMID:37458506

Abstract

摘要

相似文献

Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.

J Eur Acad Dermatol Venereol. 2023 Dec;37(12):e1426-e1429. doi: 10.1111/jdv.19348. Epub 2023 Jul 21.

Dose reduction of dupilumab in atopic patients with controlled atopic dermatitis: A safe and effective practice?

J Eur Acad Dermatol Venereol. 2023 May;37(5):e691-e692. doi: 10.1111/jdv.18908. Epub 2023 Feb 6.

Dose tapering of dupilumab in patients with persistently controlled atopic dermatitis: a Spanish multicenter cohort study.

Int J Dermatol. 2024 Mar;63(3):402-404. doi: 10.1111/ijd.17030. Epub 2024 Jan 16.

Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients With Moderate-to-Severe Atopic Dermatitis Treated With Dupilumab.

Dermatitis. 2024 Jan-Feb;35(S1):S107-S108. doi: 10.1089/derm.2023.0052. Epub 2023 Aug 18.

Benefits of treatment with dupilumab for children aged 6-11 years with severe atopic dermatitis.

Br J Dermatol. 2023 Jul 17;189(2):e39. doi: 10.1093/bjd/ljad201.

Reanalysis Following Removal of Participants From 1 Site in Multicenter Trial of Upadacitinib vs Dupilumab for Atopic Dermatitis.

JAMA Dermatol. 2024 Mar 1;160(3):370. doi: 10.1001/jamadermatol.2023.6198.

A 52-week update of a multicentre Italian real-world experience on effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis.

J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e384-e388. doi: 10.1111/jdv.18648. Epub 2022 Oct 18.

Dupilumab therapy in children aged 2-12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.

J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e35-e38. doi: 10.1111/jdv.19409. Epub 2023 Aug 24.

Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: A real-world retrospective study.

J Dermatol. 2024 Mar;51(3):e63-e65. doi: 10.1111/1346-8138.17017. Epub 2023 Nov 10.

Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab.

J Invest Dermatol. 2023 Sep;143(9):1822-1825.e3. doi: 10.1016/j.jid.2023.03.1659. Epub 2023 Mar 28.

Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis.

作者信息

机构信息

出版信息

相似文献